美国食品药品监督管理局（FDA）提出在化学、生产和控制（chemistry， manufacturing and control，CMC）方面给予细胞与基因疗法更大灵活性，这对CRISPR Therapeutics（CRSP）和bluebird bio（BLUE）等开发商构成积极转变。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.